医学
卵巢癌
流行病学
人口
入射(几何)
肿瘤科
癌症
癌症流行病学
妇科
内科学
乳腺癌
环境卫生
光学
物理
作者
Tomi T. Kanninen,Dimitrios Nasioudis,Giovanni Sisti,Kevin Holcomb,Mariarosaria Di Tommaso,Susan Khalil,Anar Gojayev,Steven S. Witkin
出处
期刊:International Journal of Gynecological Cancer
[BMJ]
日期:2017-05-01
卷期号:27 (4): 659-667
被引量:10
标识
DOI:10.1097/igc.0000000000000950
摘要
Objective The last large study of second primary tumors (SPTs) in women with ovarian cancer was published in 1996, prior to major changes in the differential diagnosis and treatment. The present study reports on the incidence of SPTs in a contemporary cohort of patients with a diagnosis of ovarian cancer. Methods Ovarian cancer patients with a diagnosis of an ovarian malignancy between 1992 and 2012 were identified and characterized from 13 registries of the Surveillance, Epidemiology, and End Results database. Results Of 41,073 women with a diagnosis of an ovarian malignancy between 1992 and 2012, 1831 (4.5%) developed a microscopically confirmed SPT. There was no significant difference in the risk of developing an SPT at all sites between women with an ovarian cancer and the general population. There was an elevated risk of site-specific SPTs of the small intestine, vagina, thyroid gland, and acute nonlymphocytic leukemia in ovarian cancer patients compared with the general Surveillance, Epidemiology, and End Results population. Conversely, the risk of lung and non-Hodgkin lymphoma was significantly decreased in women with ovarian cancer. An elevated risk of SPTs was observed in women with mucinous, endometrioid, and germ cell tumors. White women had an overall decreased risk of developing a second primary solid tumor, whereas American Indian and Asian/Pacific Islander women had an overall increased risk of an SPT at any site. Conclusions The incidence of SPTs in women with ovarian cancer was not significantly different as compared with the general population. However, divergent rates of SPTs in relation to histology, latency, age, and race were observed.
科研通智能强力驱动
Strongly Powered by AbleSci AI